These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 8904813

  • 1. 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship.
    Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Fujikura T.
    Chem Pharm Bull (Tokyo); 1996 Oct; 44(10):1865-70. PubMed ID: 8904813
    [Abstract] [Full Text] [Related]

  • 2. Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives.
    Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Honda K, Asano M, Fujita S, Furuya T, Fujikura T.
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):2910-4. PubMed ID: 1839245
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of YM435, a dopamine DA1 receptor agonist, in a canine model of ischemic acute renal failure.
    Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1998 Nov; 31(5):803-7. PubMed ID: 9809482
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological and pharmacokinetic characteristics of YM435, a novel dopamine DA1-receptor agonist, in anaesthetized dogs.
    Yatsu T, Miyamoto I, Kaneko-Takanuki F, Watanabe T, Takenaka T.
    J Pharm Pharmacol; 1997 Sep; 49(9):892-6. PubMed ID: 9306257
    [Abstract] [Full Text] [Related]

  • 6. Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature.
    Yatsu T, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1997 Aug; 29(2):229-32. PubMed ID: 9251904
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435.
    Takenaka T, Forster H, Epstein M.
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1154-9. PubMed ID: 8095547
    [Abstract] [Full Text] [Related]

  • 9. Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue.
    Riggs RM, Nichols DE, Foreman MM, Truex LL, Glock D, Kohli JD.
    J Med Chem; 1987 Aug; 30(8):1454-8. PubMed ID: 2956423
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of YM435, a novel dopamine DA1 receptor agonist, in a canine model of acute congestive heart failure.
    Yatsu T, Arai Y, Sudoh K, Shibasaki M, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1998 May; 30(5):733-7. PubMed ID: 9559326
    [Abstract] [Full Text] [Related]

  • 12. Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs.
    Iwatsuki K, Ren LM, Chiba S.
    Eur J Pharmacol; 1992 Aug 06; 218(2-3):237-41. PubMed ID: 1425944
    [Abstract] [Full Text] [Related]

  • 13. Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats.
    Yatsu T, Aoki M, Inagaki O.
    Eur J Pharmacol; 2003 Feb 14; 461(2-3):191-5. PubMed ID: 12586214
    [Abstract] [Full Text] [Related]

  • 14. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys.
    Rosenzweig-Lipson S, Bergman J.
    Eur J Pharmacol; 1994 Aug 01; 260(2-3):237-41. PubMed ID: 7988649
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and pharmacological evaluation of 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives as specific bradycardic agents.
    Kakefuda A, Watanabe T, Taguchi Y, Masuda N, Tanaka A, Yanagisawa I.
    Chem Pharm Bull (Tokyo); 2003 Apr 01; 51(4):390-8. PubMed ID: 12672990
    [Abstract] [Full Text] [Related]

  • 16. Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-py rim ido [6,1-a]isoquinolin-4-ones.
    Lal B, Dohadwalla AN, Dadkar NK, D'Sa A, de Souza NJ.
    J Med Chem; 1984 Nov 01; 27(11):1470-80. PubMed ID: 6492077
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and pharmacological evaluation of 4-phenoxy-1,2,3,4-tetrahydroisoquinolines and 4,5,6,6a-tetrahydrochromeno[2,3,4-de]isoquinolines.
    Giorgioni G, Ruggieri S, Claudi F, Di Stefano A, Ljung E, Carlsson T.
    Med Chem; 2008 Jan 01; 4(1):1-10. PubMed ID: 18220966
    [Abstract] [Full Text] [Related]

  • 18. Synergistic renal effects of RS-10085, an ace inhibitor, and fenoldopam, a DA1 agonist, in the rat.
    McClelland DL, Rosenkranz RP.
    Proc West Pharmacol Soc; 1988 Jan 01; 31():87-90. PubMed ID: 2905468
    [No Abstract] [Full Text] [Related]

  • 19. Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines.
    Jacob JN, Nichols DE, Kohli JD, Glock D.
    J Med Chem; 1981 Aug 01; 24(8):1013-5. PubMed ID: 7328594
    [Abstract] [Full Text] [Related]

  • 20. 5-Isoquinolinesulfonamide derivatives. III. Synthesis and vasodilatory activity of 1-(5-isoquinoline-sulfonyl)piperazine derivatives.
    Morikawa A, Sone T, Asano T.
    Chem Pharm Bull (Tokyo); 1992 Mar 01; 40(3):770-3. PubMed ID: 1611692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.